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INTRODUCTION
Dramatic changes in the endocrine system occur
in women at menopause. The decline in estrogen
production results in various degenerative condi-
tions, such as osteoporosis and atherosclerosis. Hor-
mone replacement therapy (HRT) is widely used
to prevent or delay the occurrence of these disor-
ders in postmenopausal women. Estrogen modu-
lates the production of cytokines since immuno-
competent cells possess estrogen receptors (1, 2).
Inflammatory cytokines such as interleukin-1
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(IL-1), IL-6 and tumor necrosis factor-α (TNF-α)
are known to be bone-resorbing cytokines based
on many experimental models (3-5). There are
many reports demonstrating that estrogen replace-
ment decreases the production of IL-1, IL-6, IL-12
and TNF-α by peripheral blood mononuclear cells
(PBMC) (6, 7) and whole blood cultures (8). We
have also demonstrated that HRT inhibited the pro-
duction of IL-1β, IL-4, IL-10, interferon-γ (IFN-γ)
and TNF-α in whole blood cultures (9-11) since the
whole blood assay is a potentially valuable tool for
assessing cellular immune function (12, 13).
Raloxifene, a non-steroidal benzothiophene de-
rivative classified as a selective estrogen receptor
modulator (SERM), has been used for the treat-
ment of postmenopausal osteoporosis. Although
raloxifene binds with high affinity to the estrogen
receptor, the conformation of the ligand/receptor
complex for raloxifene and estrogen differs, result-
ing in the differences seen in the pharmacological
properties of raloxifene and estrogen. Recently,
raloxifene has been reported to have effects on cir-
culating cytokines such as IL-6 and TNF-α, but the
results of studies on changes in these cytokines
caused by raloxifene were inconsistent (14-17).
The effects of raloxifene on production of bone-
resorbing cytokines were also discrepant because
raloxifene treatment inhibited the production of
IL-6 and TNF-α in whole blood cultures but not
the production of IL-1β in PBMC in postmeno-
pausal women (15, 18). Furthermore, the effects of
raloxifene therapy on production of cytokines such
as IL-4, IFN-γ and IL-12, which acts as a critical
bridge between the innate and acquired immune
systems, remain to be established.
The aims of this study were to determine the
effects of raloxifene therapy for 3 months and 6
months on cytokines in whole blood cultures and to
compare with in vitro effects of raloxifene on stimu-
lated secretion of cytokines in whole blood cultures.
MATERIALS AND METHODS
Subjects
Sixteen women were enrolled in this study after
they gave informed consent. This project had been
approved by the Institutional Review Broad of the
University of Tokushima, Institute of Health Bi-
osciences. The subjects included 10 untreated post-
menopausal women (ages, 50 to 65 years ; mean
age, 56.6 years) and 6 untreated postmenopausal
women with osteopenia (ages, 52 to 65 years ; mean
age, 56.2 years) from the Outpatient Clinic of the De-
partment of Obstetrics and Gynecology, Tokushima
University Hospital. The subjects had no overt dis-
ease and their peripheral blood cell counts, differ-
ential leukocyte count, and results of liver and re-
nal function tests were within normal limits.
The 6 postmenopausal women with osteopenia
received oral administration of 60 mg raloxifene
HCl (Evista, Chugai, Japan) every day. Blood sam-
ples for cytokine evaluation were drawn into tubes
before and 3 to 6 months after the start of raloxifene
therapy.
Reagents
Raloxifene (LY139481) was kindly provided by
Lilly Research Laboratories (Indianapolis, IN, USA).
We used the following reagents : RPMI 1640 (Gibco,
Grand Island, NY, USA), lipopolysaccharide (LPS)
from Esherichis coli 055 (Difco, Elkhart, IN, USA),
phytohemeagglutinin (PHA) (Sigma, St Louis, Mo,
USA), and Ficoll-Paque Plus (Amersham Pharma-
cia Biotech AB, Uppsala, Sweden).
Ex vivo study
Whole blood cultures were prepared using previ-
ously described methods (9, 10). In brief, 1 ml of
peripheral blood was withdrawn into a heparinized
(10 U/ml) tube, and within 1 h, 0.1 ml of heparinized
blood was cultured in a 24-well multicluster plate
in 1 ml RPMI 1640 containing 10% fetal calf serum
with 1 μg/ml LPS or 10 μg/ml PHA at 37 for
24 h. The culture supernatants were collected and
stored at -40until assayed.
In vitro study
The production of cytokines by peripheral blood
cells from postmenopausal women was examined
by whole blood culture. One ml of peripheral blood
was withdrawn into a heparinized (10 U/ml) tube,
and within 1 h, 0.1 ml of heparinized blood was cul-
tured in a 24-well multicluster plate in 1 ml RPMI
1640 alone (control) or with raloxifene at doses
of 10-10, 10-9, 10-8 and 10-7 M at 37for 12 h. Then
whole blood cultures were stimulated by the addi-
tion of 100 ng/ml LPS or 1 μg/ml PHA at 37for
24 h. The culture supernatants were collected and
stored at -40until assayed.
Measurement of concentrations of cytokines
Concentrations of IL-1β, IL-4, IL-6, TNF-α and
IFN-γ in the supernatants were measured using
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the respective human ELISA kits (eBioscience, San
Diego, CA, USA) according to the manufacturer’s
instructions. The sensitivity level of the kits was
4 pg/ml. The intra- and interassay coefficients of
variation were less than 10%. The concentration of
IL-12p40 was measured using a human ELISA kit
(R&D Systems, Minneapolis, MN, USA) according
to the manufacturer’s instructions. The sensitivity
level of the kit was 15 pg/ml. The intra- and inter-
assay coefficients of variation were 4.3% and 9.3%,
respectively. The concentration of IL-12p70 was
measured using a human ELISA kit (BioSource
Internationnal, Camarillo, CA, USA) according to
the manufacturer’s instructions. The sensitivity level
of the kit was 0.5 pg/ml. The intra- and interassay
coefficients of variation were 9.5% and 8.7%, respec-
tively.
Assessment of cell viability
Viability of cells treated with raloxifene was de-
termined by the trypan blue dye exclusion test. In
brief, peripheral blood mononuclear cells (PBMC)
were isolated by fractionation on Ficoll-Paque Plus.
The interface was removed and washed twice in
RPMI 1640. Isolated PBMC were incubated as a
density of 5105/ml in RPMI 1640 alone (control)
or with different concentrations of raloxifene (10-10,
10-9, 10-8 and 10-7 M) at 37for 36 h. After the in-
cubation, cells were stained with 0.2% trypan blue
for 15 min. The number of stained cells among 200
cells was counted.
Statistical analysis
Statistical analyses comparing treatment groups
were performed by the Wilcoxon signed-rank test.
Values of p<0.05 were considered to be significant.
The StatView 4.1 program (Abacus Concepts, Inc.,
Berkeley, CA) was used for statistical analysis.
RESULTS
Ex vivo study
Raloxifene therapy for 3 and 6 months induced a
significant decrease in LPS-stimulated production
of IL-1β (p<0.05), IL-6 (p<0.05) and TNF-α (p<
0.05) in postmenopausal women (Fig. 1). Raloxifene
therapy for 3 and 6 months also induced a significant
decrease in LPS-stimulated production of IL-12p40
(p<0.05) and IL-12p70 (p<0.05) (Fig. 2). However,
there was no significant change in either IL-4 or
IFN-γ after 3 and 6 months of raloxifene therapy
(Fig. 3).
Figure 1. Effects of raloxifene therapy on production of IL-1β (A), IL-6 (B) and TNF-α (C) by 1 μg/ml LPS-stimulated whole
blood cells from postmenopausal women with osteopenia. * indicates significance of difference from levels before therapy (p0.05).
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In vitro study
There was a significant decrease
in IL-1β and IL-6 compared to ba-
sal levels at raloxifene doses of
10-9, 10-8 and 10-7 M (p<0.05) (Fig.
4A, 4B). There was a significant
decrease in TNF-α compared to
basal levels at raloxifene doses of
10-8 and 10-7 M (p<0.05) (Fig. 4C).
There was a significant decrease
in IL-12p40 compared to basal lev-
els at raloxifene doses of 10-9, 10-8
and 10-7 M (p<0.05) (Fig. 5A), and
there was a significant decrease in
IL-12p70 compared to basal levels
at a raloxifene dose of 10-10 and 10-8
M (p<0.05) (Fig. 5B).
There was a significant decrease
in IFN-γ compared to basal levels
at raloxifene doses of 10-10, 10-9, 10-8
and 10-7 M (p<0.05) (Fig. 6A), and
there was a significant decrease in
IL-4 compared to basal levels at
raloxifene doses of 10-8 and 10-7 M
(p<0.05) (Fig. 6B).
Cell viability
The viability of cells treated with
raloxifene at doses of 10-10, 10-9, 10-8
Figure 2. Effects of raloxifene therapy on production of IL-12p40 (A) and IL-12p
70 (B) by 1 μg/ml LPS-stimulated whole blood cells from postmenopausal women
with osteopenia. * indicates significance of difference from levels before therapy
(p0.05).
Figure 4. Effects of raloxifene at
concentrations of 10-10 M to 10-7 M on
100 ng/ml LPS-stimulated production
of IL-1β (A), IL-6 (B) and TNF-α (C)
in whole blood cultures. Values are
percentage of basal (n=10). Solid lines
shows means +/- SD. * indicates sig-
nificance of difference from basal (p
0.05).
Figure 3. Effects of raloxifene therapy on production of IL-4(A) and IFN-γ (B)
by 10 μg/ml PHA-stimulated whole blood cells from postmenopausal women with
osteopenia. * indicates significance of difference from levels before therapy (p0.05).
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and 10-7 M was not change compared to that of con-
trol cells (data not shown).
DISCUSSION
In the present study, we demonstrated that
raloxifene therapy for 3 and 6 months decreases
LPS-stimulated production of IL-1β, IL-6, IL-12p40,
IL-12p70 and TNF-α but not PHA-stimulated pro-
duction of IL-4 and IFN-γ in whole blood cultures,
suggesting that modulation of bone-resorbing cy-
tokines such as IL-1β, IL-6 and TNF-α could play
a role in the mechanisms of the osteoprotective
effect of raloxifene. We used the whole blood cul-
ture method to determine LPS- or PHA-stimulated
cytokine production in ex vivo and in vitro studies.
Since isolation of PBMC by hyperosmolar solutions
such as Ficoll-Hypaque and their culture ex vivo
could modify the function of PBMC compared with
that in vivo (19), the whole blood culture method
seems to be the best method for mimicking in vivo
conditions of immune reactions (12).
Raloxifene therapy has been reported to have
effects on the production or circulating levels of
bone-resorbing cytokines such as IL-1β, IL-6 and
TNF-α, but results of studies on changes in these
cytokines were inconsistent. Gianni et al . reported
that the mRNA expression of IL-6 and TNF-α was
reduced by raloxifene therapy for 6 months (15).
On the other hand, raloxifene treatment did not
reduce circulating levels of IL-6 and TNF-α (16,
17), although Walsh et al . reported that raloxifene
therapy significantly decreased serum TNF-α level
but not IL-6 level (14). Furthermore, Rogers et al .
demonstrated that raloxifene therapy did not modu-
late 500 ng/ml LPS-stimulated production of IL-1β
by using a whole bloody assay (18). However, we
have shown that raloxifene therapy had an inhibi-
tory effect on LPS-stimulated production of IL-1β,
IL-6 and TNF-α, which is consistent with our pre-
vious results using HRT (11). In this study, whole
blood cells were stimulated by 1 μg/ml LPS, which
is a higher concentration than that used by Rogers
Figure 5. Effects of raloxifene at concentrations of 10-10 M to 10-7 M on 100 ng/ml LPS-stimulated production of IL-12p40 (A) and
IL-12p70 (B) in whole blood cultures. Values are percentage of basal (n=10). Solid lines shows means +/- SD. * indicates signifi-
cance of difference from basal (p0.05).
Figure 6. Effects of raloxifene at concentrations of 10-10 M to 10-7 M on 1 μg/ml PHA-stimulated production of IL-4(A) and IFN-γ
(B) in whole blood cultures. Values are percentage of basal (n=10). Solid lines shows means +/SD. * indicates significance of dif-
ference from basal (p<0.05).
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et al . Since LPS has strong stimulatory effects that
could outweigh any potential inhibitory effect of
raloxifene, the reason for the difference in the pro-
duction of IL-1β is unclear.
In the in vitro study, raloxifene at concentrations
of 10-9-10-7 M significantly inhibited LPS-stimulated
production of IL-1β and IL-6 and raloxifene at con-
centrations of more than 10-8 M significantly inhib-
ited LPS-stimulated production of TNF-α. Although
we did not observe a dose-dependent response of
raloxifene on IL-1β, IL- 6 and TNF-α production, a
raloxifene dose of 10-9 M was required to show a sig-
nificant response. It is estimated that a raloxifene
dose of 10-9 M is equivalent to the circulating con-
centration in raloxifene-treated women because
the maximum plasma concentration after multiple
dosing of raloxifene at 60 mg/d is 1.36 ng/ml, which
is equivalent to 2.610-9 M (20). Taranta et al . dem-
onstrated that raloxifene inhibited the mRNA ex-
pression of IL-1β and IL-6 at a low concentration of
10-10 M in in vitro murine osteoblasts (21). How-
ever, in human osteoblastic cells, treatment with
raloxifene at doses (10-8, 10-7, 10-6 M), but not at
doses (10-12 -10-9 M), resulted in a reduction in the
spontaneous production of IL-1β and IL-6 (22). Fur-
thermore, Rogers et al . demonstrated that raloxifene
does not modulate spontaneous production of IL-1β
in vitro by using a whole bloody assay (18). In our
study, whole blood cells were stimulated by the
addition of 100 ng/ml LPS after preincubation
with raloxifene for 12 h because simultaneous ad-
ministration of raloxifene and LPS might negate
the inhibitory effect of raloxifene due to the strong
stimulatory effect of LPS. The discrepancy in re-
sults of in vitro studies may be explained by differ-
ences in the cells cultured and the method with or
without stimulation by LPS.
To the best of our knowledge, this is the first
study showing that raloxifene inhibited the pro-
duction of IL-12 ex vivo and in vitro . IL-12 is known
to be an inflammatory cytokine produced primarily
by phagocytic cells and antigen-presenting cells.
IL-12 plays a role in the early inflammatory re-
sponse to infection and in the generation of T
helper type 1 (Th1) cells while inhibiting the gen-
eration of Th2 cells (23). IL-12 is composed of a
heavy chain (p40) and a light chain (p35), forming
a disulfite-linked heterodimer (p70) (24). IL-12p
40 is produced primarily by activated monocytes/
macrophages, while IL-12p35 is produced con-
stantly. In this study, raloxifene therapy for 6 months
significantly reduced LPS-stimulated production
of IL-12p40 and IL-12p70, although a concentration
(10-9 M) of raloxifene inhibited LPS-stimulated
production of IL-12p40 but not that of IL-12p70. On
the other hand, it has been shown that 17β -estradiol
at a pregnancy concentration significantly inhibited
the production of IL-12p70 in whole blood stimu-
lated with a mixture of 1 μg/ml LPS and 5 μg/ml
PHA (8). Elenkov et al . also demonstrated that
whole blood IL-12 production in pregnant women
was decreased 2-fold compared with that in women
during the postpartum period (25), suggesting that
raloxifene as well as 17β -estradiol has an inhibitory
effect on the production of IL-12.
Th1 cells have been found to produce IFN-γ and
IL-2, whereas Th2 cells produce different cytoki-
nes such as IL-4 and IL-5. It has been reported that
raloxifene therapy caused a decrease in serum IL-4
levels (26). In our in vitro study, raloxifene inhib-
ited 1 μg/ml PHA-stimulated production of IL-4
and IFN-γ in a dose-dependent manner. However,
in our ex vivo study, raloxifene therapy did not
modulate 10 μg/ml PHA-stimulated production of
IL-4 and IFN-γ by whole blood cells. In previously
published articles, we have shown that HRT had
inhibitory effects on the production of IL-4 and
IFN-γ in 10 μg/ml PHA-stimulated cultures (9, 10).
Since 10 μg/ml PHA might negate the inhibitory ef-
fect of raloxifene due to the strong stimulatory ef-
fect of PHA, further study is needed to clarify the
effect of raloxifene therapy on PHA-stimulated pro-
duction of IL-4 and IFN-γ.
In conclusion, we have shown that raloxifene ther-
apy and a raloxifene compound have inhibitory ef-
fects on the production of bone-resorbing or proin-
flammatory cytokines including IL-1β, IL-6, IL-12
and TNF-α, suggesting that raloxifene may play a
role in bone resorption and formation due to sup-
pression of the production of these cytokines.
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